77 related articles for article (PubMed ID: 11921502)
1. Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients.
Dailey G; Kim MS; Lian JF
J Int Med Res; 2002; 30(1):71-9. PubMed ID: 11921502
[TBL] [Abstract][Full Text] [Related]
2. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus.
Dailey G; Kim MS; Lian JF
Clin Ther; 2001 Aug; 23(8):1311-20. PubMed ID: 11558867
[TBL] [Abstract][Full Text] [Related]
3. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
[TBL] [Abstract][Full Text] [Related]
4. Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy.
Corrao G; Romio SA; Zambon A; Merlino L; Bosi E; Scavini M
Eur J Clin Pharmacol; 2011 Mar; 67(3):289-99. PubMed ID: 21088829
[TBL] [Abstract][Full Text] [Related]
5. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
[TBL] [Abstract][Full Text] [Related]
7. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria.
Winkelmayer WC; Stedman MR; Pogantsch M; Wieninger P; Bucsics A; Asslaber M; Bauer R; Burkhardt T; Schautzer A; Brookhart MA;
Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):57-65. PubMed ID: 21182153
[TBL] [Abstract][Full Text] [Related]
8. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
Hansen RA; Farley JF; Droege M; Maciejewski ML
Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
[TBL] [Abstract][Full Text] [Related]
9. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.
Eurich DT; Simpson SH; Majumdar SR; Johnson JA
Pharmacotherapy; 2005 Jun; 25(6):810-6. PubMed ID: 15927899
[TBL] [Abstract][Full Text] [Related]
10. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study.
Andersson C; Olesen JB; Hansen PR; Weeke P; Norgaard ML; Jørgensen CH; Lange T; Abildstrøm SZ; Schramm TK; Vaag A; Køber L; Torp-Pedersen C; Gislason GH
Diabetologia; 2010 Dec; 53(12):2546-53. PubMed ID: 20838985
[TBL] [Abstract][Full Text] [Related]
11. Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients.
Grimes RT; Bennett K; Tilson L; Usher C; Smith SM; Henman MC
Br J Clin Pharmacol; 2015 Jun; 79(6):1000-9. PubMed ID: 25521800
[TBL] [Abstract][Full Text] [Related]
12. The prescription pattern of initial treatment for type 2 diabetes in Beijing from 2011 to 2015.
Wang X; Cao Y; Wu Y; Yang C; Song J; Tian Y; Wang M; Li M; Wu Y; Hu Y
Medicine (Baltimore); 2019 Feb; 98(8):e14370. PubMed ID: 30813137
[TBL] [Abstract][Full Text] [Related]
13. Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database.
Rascati KL; Richards KM; Lopez D; Cheng LI; Wilson JP
Clin Ther; 2011 Dec; 33(12):2016-20. PubMed ID: 22101160
[TBL] [Abstract][Full Text] [Related]
14. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of steady-dose metformin in type 2 diabetes mellitus: a retrospective study.
Drzewoski J; Czupryniak L
Med Sci Monit; 2003 Jun; 9(6):CR240-3. PubMed ID: 12824953
[TBL] [Abstract][Full Text] [Related]
16. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea.
Thayer S; Arondekar B; Harley C; Darkow TE
Ann Pharmacother; 2010 May; 44(5):791-9. PubMed ID: 20371759
[TBL] [Abstract][Full Text] [Related]
17. Nonadherence as a predictor of antidiabetic drug therapy intensification (augmentation).
Kogut SJ; Andrade SE; Willey C; Larrat EP
Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):591-8. PubMed ID: 15362081
[TBL] [Abstract][Full Text] [Related]
18. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
Wahlqvist ML; Lee MS; Hsu CC; Chuang SY; Lee JT; Tsai HN
Parkinsonism Relat Disord; 2012 Jul; 18(6):753-8. PubMed ID: 22498320
[TBL] [Abstract][Full Text] [Related]
19. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
[TBL] [Abstract][Full Text] [Related]
20. [One year persistence of metformin monotherapy versus metformin/sitagliptin fixed dose combination].
Simonyi G; Ferenci T
Orv Hetil; 2016 Apr; 157(16):618-22. PubMed ID: 27063429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
